Learn More About Our Rotations
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Medical Directors Arup Medical Directors and Consulting Faculty | 2015
MEDICAL DIRECTORS ARUP MEDICAL DIRECTORS AND CONSULTING FACULTY | 2015 MAY 2015 www.aruplab.com Information in this brochure is current as of May 2015. All content is subject to change. Please contact ARUP Client Services at (800) 522-2787 with any questions or concerns. ARUP LABORATORIES ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. Located in Salt Lake City, Utah, ARUP offers in excess of 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. Rather than competing with its clients for physician office business, ARUP chooses instead to support clients’ existing test menus by offering complex and unique tests, with accompanying consultative support, to enhance their abilities to provide local and regional laboratory services. ARUP’s clients include many of the nation’s university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®. Since its formation in 1984 by the Department of Pathology at the University of Utah, ARUP has founded its reputation on reliable and consistent laboratory testing and service. This simple strategy contributes significantly to client satisfaction. When ARUP conducts surveys, clients regularly rate ARUP highly and respond that they would recommend ARUP to others. As the most responsive source of quality information and knowledge, ARUP strives to be the reference laboratory of choice for community healthcare systems. -
Understanding Your Pathology Report: Benign Breast Conditions
cancer.org | 1.800.227.2345 Understanding Your Pathology Report: Benign Breast Conditions When your breast was biopsied, the samples taken were studied under the microscope by a specialized doctor with many years of training called a pathologist. The pathologist sends your doctor a report that gives a diagnosis for each sample taken. Information in this report will be used to help manage your care. The questions and answers that follow are meant to help you understand medical language you might find in the pathology report from a breast biopsy1, such as a needle biopsy or an excision biopsy. In a needle biopsy, a hollow needle is used to remove a sample of an abnormal area. An excision biopsy removes the entire abnormal area, often with some of the surrounding normal tissue. An excision biopsy is much like a type of breast-conserving surgery2 called a lumpectomy. What does it mean if my report uses any of the following terms: adenosis, sclerosing adenosis, apocrine metaplasia, cysts, columnar cell change, columnar cell hyperplasia, collagenous spherulosis, duct ectasia, columnar alteration with prominent apical snouts and secretions (CAPSS), papillomatosis, or fibrocystic changes? All of these are terms that describe benign (non-cancerous) changes that the pathologist might see under the microscope. They do not need to be treated. They are of no concern when found along with cancer. More information about many of these can be found in Non-Cancerous Breast Conditions3. What does it mean if my report says fat necrosis? Fat necrosis is a benign condition that is not linked to cancer risk. -
Clinical Microbiology Core Rotation
C:\Documents and Settings\jdnoll\Desktop\UofFCytolRot10.doc CYTOPATHOLOGY ROTATION Site: University of Florida-Gainesville/ Shands North & South Tower Faculty: Peter Drew, M.D. (4-4969) Larry J. Fowler, M.D., Cytology Director (4-4959) Jacquelyn Knapik, M.D. (4-3887) Li Lu, M.D, PhD (63-6440) Demaretta Rush, M.D. (5-3364) Edward Wilkinson, M.D. (4-4962) Anthony Yachnis, M.D., Anatomic Pathology Director (4-4951) Current Cytopathology Fellow Charlene M. Lewis, CT (ASCP) Superviser Deborah A. Carroll, CT, (ASCP) Patricia Christensen, CT (ASCP) David A. Lemire, CT (ASCP) Rotation Periods: 12 weeks for CORE Rotation broken into three 4 week rotations (a portion of the 12 weeks may be on the VA Hospital Cytology Rotation). Offered all 12 months of any training year. I. General Organization: The cytopathology core rotation consists of three 4 week rotations (total 12 weeks) routinely placed within the 1st thru 4th PGY training years of a 4 year APCP training program. The CORE rotation may also be done in one combined 12 week rotation upon special request. Cervical biopsies and local gynecologic excisions are signed out in tandem with cytology specimens (correlation of surgical and cytologic specimens). The first 4 week's rotation, residents review the day's cases at the time of sign-out with the faculty member on service. During the second and third 4 week rotations residents preview cases before sign-out, render preliminary interpretations, and receive feedback at sign out (graduated responsibility). Fellows preview the slides before sign-out and render interpretations, and have the option to attend sign-out or receive feedback from the attending pathologist later (graduated responsibility). -
A Comparison of Imaging Modalities for the Diagnosis of Osteomyelitis
A comparison of imaging modalities for the diagnosis of osteomyelitis Brandon J. Smith1, Grant S. Buchanan2, Franklin D. Shuler2 Author Affiliations: 1. Joan C Edwards School of Medicine, Marshall University, Huntington, West Virginia 2. Marshall University The authors have no financial disclosures to declare and no conflicts of interest to report. Corresponding Author: Brandon J. Smith Marshall University Joan C. Edwards School of Medicine Huntington, West Virginia Email: [email protected] Abstract Osteomyelitis is an increasingly common pathology that often poses a diagnostic challenge to clinicians. Accurate and timely diagnosis is critical to preventing complications that can result in the loss of life or limb. In addition to history, physical exam, and laboratory studies, diagnostic imaging plays an essential role in the diagnostic process. This narrative review article discusses various imaging modalities employed to diagnose osteomyelitis: plain films, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, bone scintigraphy, and positron emission tomography (PET). Articles were obtained from PubMed and screened for relevance to the topic of diagnostic imaging for osteomyelitis. The authors conclude that plain films are an appropriate first step, as they may reveal osteolytic changes and can help rule out alternative pathology. MRI is often the most appropriate second study, as it is highly sensitive and can detect bone marrow changes within days of an infection. Other studies such as CT, ultrasound, and bone scintigraphy may be useful in patients who cannot undergo MRI. CT is useful for identifying necrotic bone in chronic infections. Ultrasound may be useful in children or those with sickle-cell disease. Bone scintigraphy is particularly useful for vertebral osteomyelitis. -
Cytopathology Fellowship Faculty of Medicine, Postgraduate Medical Education
Cytopathology Fellowship Faculty of Medicine, Postgraduate Medical Education Institution: McGill University and McGill University Health Centre Location: Department of Pathology, MUHC and Duff Medical Building Type of Fellowship: One year clinical fellowship in Cytopathology Fellowship Program Director: Dr. Manon Auger Program Information Number of fellowship positions requested: One Academic affiliation: McGill University Name of hospitals involved in training: McGill University Health Centre (MUHC) Background: The fellowship will be principally based at the MUHC. This one-year post-residency clinical fellowship offers a comprehensive, integrated exposure to the field of Cytopathology. The cytological specimens handled at the MUHC include approximately 50,000 gynecological specimens per year (including approximately 7000 colposcopic specimens) as well as 10,000 non-gynecological specimens (including approximately 4000 fine needle aspirates). Exposure to liquid- based cytology is provided. Research activity and publications: The fellow will be expected to participate in at least one major research project involving, at minimum, a review of a series of cases (i.e., not simply a case report) with a view to publication in a peer-reviewed journal (i.e. not only presentation at a meeting). In addition, other research projects may be carried out, including case reports. Mission and objectives: The general mission of the fellowship is to provide training in the interpretation of cytopathology with a view to learn the entire spectrum of reactive -
Simple Technique to Identify Haemosiderin in Immunoperoxidase Stained Sections
J Clin Pathol: first published as 10.1136/jcp.37.10.1190 on 1 October 1984. Downloaded from 1190 Technical methods Phosphate buffer at pH 8*0 gave the sharpest 2 Rozenszajn L, Leibovich M, Shoham D, Epstein J. The esterase staining reactions, although there was little differ- activity in megaloblasts, leukaemic and normal haemopoietic cells. Br J Haematol 1968; 14:605-19. ence at pH 7-0 or pH 7-5. As the buffer pH was 3Hayhoe FGJ, Quaglino D. Haematological cytochemistry. Edin- increased above pH 8-0 staining with both substrates burgh: Churchill Livingstone, 1980. became progressively weaker, especially above pH 4Li CY, Lam KW, Yam LT. Esterases in human leucocytes. J 9.0. Below pH 7-0 staining with a-naphthyl butyrate Histochem Cytochem 1973;21:1-12. Yam LT, Li CY, Crosby WH. Cytochemical identification of became weaker, and below pH 5*0 staining with monocytes and granulocytes. Am J Clin Pathol 1971;55:283- naphthol AS-D chloroacetate began to disappear. 90. 6 Armitage RJ, Linch DC, Worman CP, Cawley JC. The morphol- This work was supported by a Medical Research ogy and cytochemistry of human T-cell subpopulations defined by monoclonal antibodies and Fc receptors. Br J Haematol Council project grant. I thank Professor FGJ 1983;51:605-13. Hayhoe for valuable advice. References Requests for reprints to: Dr DM Swirsky, Department of Gomori G. Chloroacyl esters as histochemical substrates. J His- Haematological Medicine, University Clinical School, Hills tochem Cytochem 1953;1:469-70. Road, Cambridge CB2 2QL, England. Simple technique to identify identification of the two compounds on the same haemosiderin in slide. -
Soft Tissue Tumor Pathology: New Diagnostic Immunohistochemical Markers Leona A
S EMINARS IN D IAGNOSTIC P ATHOLOGY ] (2015) ]]]– ]]] Available online at www.sciencedirect.com www.elsevier.com/locate/semdp Soft tissue tumor pathology: New diagnostic immunohistochemical markers Leona A. Doyle, MD Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis St, Boston, Massachusetts article info abstract Keywords: Recent insights into the pathogenesis of various soft tissue tumors, along with the Soft tissue identification of recurrent molecular alterations characteristic of specific tumor types, Tumor have resulted in the development of many diagnostically useful immunohistochemical Sarcoma markers. In some cases, expression of these markers is significantly associated with Immunohistochemistry distinctive clinical and histologic features, which may impart prognostic or predictive Molecular genetics information. This review outlines new diagnostic immunohistochemical markers in soft tissue tumor pathology, emphasizing their utility in clinical practice and potential pitfalls, molecular correlates and clinical associations. & 2015 Elsevier Inc. All rights reserved. Introduction shows MYC amplification. Finally, so-called lineage specific markers, which tend to show nuclear staining and in general fi Over the last 10 years, many novel immunohistochemical are not strictly speci c to a given lineage, have also emerged markers for use in the evaluation of soft tissue tumors have as useful markers, not only in soft tissue pathology but also been described. This has largely been due to new insights -
Bone & Soft Tissue Pathology Fellowship
Bone & Soft Tissue Pathology Fellowship The Department of Pathology at Memorial Availability: July 2023 Sloan Kettering Cancer Center offers a one- year fellowship training program in bone and Number of Positions: One soft tissue pathology. The fellowship begins on Length of Program: One Year July 1st and ends on June 30th the following year. All fellows should have completed Deadline: August 1, for appoint- residency training in anatomic pathology and ments beginning 2 years later (ie. be certified (or eligible for certification) by 8/1/2021 for start date 7/1/2023). the American Board of Pathology. Early application is acceptable because completed applications may be During the sub-specialty fellowship year, the considered on a rolling basis. fellow will have the opportunity to study our large volume of quality in-house and submitted How to Apply: Apply Online material, departmental consultation case Only complete applications will material, as well as recommended reading of be reviewed. Once applicants have literature to achieve adequate competence submitted their applications, they will in the pathologic diagnosis, staging, and need to send the following documents: prognostication of a wide variety of bone and • Three letters of recommendation from soft tissue tumors. In addition, the fellow an institution in which the applicant will have the opportunity to perform clinico- has trained. Letters should be pathologic and molecular correlations. addressed to Dr. Ronald Ghossein, the The fellow will serve as a consultant to the program director. Please request letter oncologic pathology fellows in the orientation, writers add the following line after gross dissection and morphologic evaluation the heading (RE: Candidate’s Name, of bone and soft tissue specimens. -
Pathology and Genetics of Tumours of Soft Tissue and Bone
bb5_1.qxd 13.9.2006 14:05 Page 3 World Health Organization Classification of Tumours WHO OMS International Agency for Research on Cancer (IARC) Pathology and Genetics of Tumours of Soft Tissue and Bone Edited by Christopher D.M. Fletcher K. Krishnan Unni Fredrik Mertens IARCPress Lyon, 2002 bb5_1.qxd 13.9.2006 14:05 Page 4 World Health Organization Classification of Tumours Series Editors Paul Kleihues, M.D. Leslie H. Sobin, M.D. Pathology and Genetics of Tumours of Soft Tissue and Bone Editors Christopher D.M. Fletcher, M.D. K. Krishnan Unni, M.D. Fredrik Mertens, M.D. Coordinating Editor Wojciech Biernat, M.D. Layout Lauren A. Hunter Illustrations Lauren A. Hunter Georges Mollon Printed by LIPS 69009 Lyon, France Publisher IARCPress International Agency for Research on Cancer (IARC) 69008 Lyon, France bb5_1.qxd 13.9.2006 14:05 Page 5 This volume was produced in collaboration with the International Academy of Pathology (IAP) The WHO Classification of Tumours of Soft Tissue and Bone presented in this book reflects the views of a Working Group that convened for an Editorial and Consensus Conference in Lyon, France, April 24-28, 2002. Members of the Working Group are indicated in the List of Contributors on page 369. bb5_1.qxd 22.9.2006 9:03 Page 6 Published by IARC Press, International Agency for Research on Cancer, 150 cours Albert Thomas, F-69008 Lyon, France © International Agency for Research on Cancer, 2002, reprinted 2006 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. -
Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline Or High-Risk Lesions
- Official Statement - Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline or High-Risk Lesions Purpose To outline the management approach for borderline and high risk lesions identified on image-guided breast biopsy. Associated ASBrS Guidelines or Quality Measures 1. Image-Guided Percutaneous Biopsy of Palpable and Nonpalpable Breast Lesions 2. Performance and Practice Guidelines for Stereotactic Breast Procedures 3. Concordance Assessment Following Image-Guided Breast Biopsy Methods Literature review inclusive of recent randomized controlled trials evaluating the management of various borderline and high-risk lesions (including atypical hyperplasia, lobular neoplasia, papillary lesions, radial scars and complex sclerosing lesions, fibroepithelial lesions, mucocele-like lesions, spindle cell lesions, and pseudoangiomatous stromal hyperplasia [PASH]) identified on image-guided breast biopsies. This is not a complete systematic review but a comprehensive review of the modern literature on this subject. The ASBS Research Committee developed a consensus document which the ASBS Board of Directors reviewed and approved. Summary of Data Reviewed Percutaneous core needle biopsy (CNB) is the preferred, initial, minimally invasive diagnostic procedure for nonpalpable breast lesions or palpable breast masses.1 Concordance assessment of the histologic, imaging, and clinical findings determines further management. Discordance refers to the situation in which a breast CNB demonstrates benign histology, while the clinical or imaging findings are suspicious for malignancy. If there is discordance between imaging and pathology, histological evaluation is still needed. This can be accomplished either by repeat CNB, perhaps with consideration of larger gauge or vacuum- assisted device, or surgical excision.2-5 Some nonmalignant CNB findings are considered “borderline” because of their potential association with malignancy. -
The Papanicolaou and Frost 2019 Cytopathology Tutorial
Y 5 E Coun cil for Continuing Medical Education to provide continuing N 1 Statement of Need , D G . T N medical education for physicians. A Diagnostic cytopathology per forms a vital role in the O T S W N D S I di agnosis and treatment of non-neoplastic and neoplastic T Weill Cornell Medicine designates this live activity for a O T A O I R T 15. 0 1 P AMA PRA Category Credi t(s )™. P le sions. This course is intended to advance and develop S M maximum of H . R T R S I the knowledge base of pathologists in cytopathology. P Physicians should claim only the credit commensurate with E M U P Current criteria and concepts based on cytomorphologic the extent of their participation in the activity. S evaluation and approaches to differential diagnosis are the core need for the practice of cytopathology. This course is Maintenance of Certification designed to provide a practical update to cytopathologists, The American Board of Pathology has approved the Tutorial cytotechnologists, general pathologists and fellows/residents as a Self- Assessment Module (SAM) for Part II of the ABP in training. Main tenance of Certifica tion (MOC) program and designates this edu cational activity for a max imum of 10.0 SAM Course Goals and Objectives Credit(s). Physi cians should claim only the credit commen - This CME approved course will lead to improved practice surate with the extent of their participation in the activity. of cytopathology leading to enhanced pa tient care. At the conclusion of this course the at tendees will be able to: Disclosure of Relationships/ Content Validity • Evaluate cytologic criteria of various non-neoplastic It is the policy of Weill Cornell Medicine to adhere to and neoplastic lesions. -
Anesthesiology
Anesthesiology RESIDENCY PROGRAM AT Ocala Regional Medical Center Welcome to the AboutAnesthesiology HCA Healthcare Residency Program at Ocala Regional Medical Center The Anesthesiology Residency Program at Ocala Regional Medical Center is part of the HCA Healthcare Graduate Medical Education network. HCA Healthcare is the nation’s leading provider of quality, patient-centered care. We are also the leader in graduate medical education, all brought together by a single mission: Above all else, we are committed to the care and improvement of human life. ACGME ID: 401100212 Tracks & Positions Tracks NRMP # Available Positions Advanced 1587040A0 9 Salary PGY2 PGY3 PGY4 $55,456 $58,590 $60,630 Welcome and thank you for your interest in our program. In partnership with HCA Healthcare GME, we adhere to the mission statement, “Above all else, we are committed to the care and improvement of human life”. The Anesthesiology Residency Program is committed to training physicians in the science and practice of anesthesiology and perioperative medicine. In this context, we will train our colleagues in delivering evidence-based, high quality medical care emphasizing patient safety goals, and in which patient and family satisfaction is optimized. Excellence, collegiality, compassion, and integrity in patient care are the core tenets of our program education. We envision the residency program as a safe, positive and inspiring clinical environment to improve health outcomes and better serve our community. Sincerely, Ettore Crimi, MD Program Director Our faculty Ettore Crimi MD, Program Director • Anesthesiology Residency completed at MGH/Harvard • Cardiothoracic Fellowship completed at Stanford • Critical Care Fellowship completed at University of Florida • Subspecialty interests include critical care medicine, cardiothoracic anesthesia, and translational research.